Analysts expect that Rubius Therapeutics Inc (NASDAQ:RUBY) will announce earnings per share of ($0.51) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Rubius Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.62). Rubius Therapeutics posted earnings per share of ($0.42) during the same quarter last year, which would suggest a negative year over year growth rate of 21.4%. The firm is scheduled to report its next quarterly earnings report on Tuesday, November 12th.
On average, analysts expect that Rubius Therapeutics will report full year earnings of ($1.93) per share for the current financial year, with EPS estimates ranging from ($2.23) to ($1.40). For the next fiscal year, analysts expect that the company will report earnings of ($2.27) per share, with EPS estimates ranging from ($2.62) to ($1.47). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Rubius Therapeutics.
Rubius Therapeutics (NASDAQ:RUBY) last announced its earnings results on Tuesday, August 13th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.04). During the same quarter last year, the business earned ($3.33) earnings per share.
In related news, Director Robert Langer sold 7,500 shares of the company’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $14.94, for a total value of $112,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christopher L. Carpenter sold 47,757 shares of the company’s stock in a transaction dated Wednesday, June 19th. The stock was sold at an average price of $14.02, for a total value of $669,553.14. The disclosure for this sale can be found here. 58.40% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC bought a new position in shares of Rubius Therapeutics in the first quarter worth about $14,995,000. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Rubius Therapeutics by 147.3% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,241,299 shares of the company’s stock valued at $19,526,000 after purchasing an additional 739,449 shares during the last quarter. Nikko Asset Management Americas Inc. lifted its holdings in Rubius Therapeutics by 142.3% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,254,158 shares of the company’s stock valued at $19,728,000 after purchasing an additional 736,490 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Rubius Therapeutics by 29.1% during the 2nd quarter. Vanguard Group Inc. now owns 2,725,717 shares of the company’s stock valued at $42,876,000 after purchasing an additional 614,759 shares during the last quarter. Finally, FMR LLC lifted its holdings in Rubius Therapeutics by 8.9% during the 1st quarter. FMR LLC now owns 7,019,730 shares of the company’s stock valued at $127,057,000 after purchasing an additional 573,662 shares during the last quarter. 95.60% of the stock is owned by institutional investors.
Shares of Rubius Therapeutics stock traded up $0.61 on Friday, hitting $10.60. The company had a trading volume of 298,955 shares, compared to its average volume of 274,227. The business has a 50-day simple moving average of $13.91 and a 200-day simple moving average of $15.34. The company has a debt-to-equity ratio of 0.13, a current ratio of 18.64 and a quick ratio of 18.64. The company has a market cap of $834.03 million and a PE ratio of -4.67. Rubius Therapeutics has a 52 week low of $9.96 and a 52 week high of $26.90.
About Rubius Therapeutics
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
Featured Story: Fundamental Analysis and Choosing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.